The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
NICE recommendation of acalabrutinib for patients with treatment-naïve CLL
On March 18, 2021, it was announced that the National Institute for Health and Care Excellence (NICE) in England recommend the use of acalabrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia (CLL).
This recommendation is for patients with a TP53 mutation or 17p deletion, or for patients without these mutations but where fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab is unsuitable. As acalabrutinib is administered as a twice daily tablet, the recommendation is of particular benefit during the current COIVD-19 pandemic because patients can self-administer from home.
This recommendation comes after the European approval previously discussed on the Lymphoma Hub.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content